DATA GRAPHICS | Product Development
Daily Chart: ide-cel’s challengers in the BCMA pipeline
May 16, 2020 12:51 AM UTC
Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter for BMS-bluebird”). ...
BCIQ Company Profiles